. Author manuscript; available in PMC: 2017 Jul 27.

Published in final edited form as: Eur J Pharmacol. 1993 Nov 16;249(3):265–270. doi: 10.1016/0014-2999(93)90521-i

TABLE 3.

Percent incidence of seizures and/or other neurological symptoms following administration of various doses of either NMDA alone or CPA or CPX followed by NMDA.

Dose mg/kg	Clon/ton		Clon		Hyperact		Depr

	NMDA	CPA + NM	NMDA	CPA + NM	NMDA	CPA + NM	NMDA	CPA + NM
2A/125NM	90	10 ^a	10	40 ^a	0	0	0	50
0.5A/60NM	40	10 ^a	50	0 ^a	10	70 ^a	0	20
IA/60NM	40	10 ^a	30	0	30	50	0	20
1A/30NM	10	0	0	0	0	0	90	100

	NMDA	CPX + NM	NMDA	CPX + NM	NMDA	CPX + NM	NMDA	CPX + NM

1X/60NM	40	60	30	10 ^a	30	30	0	0
2X/60NM	40	70 ^a	30	10 ^a	30	20 ^a	0	0
1X/30NM	0	0	0	10 ^a	0	70 ^a	100	20 ^a
2X/30NM	0	0 ^a	0	10 ^a	0	80 ^a	100	10 ^a

Abbreviations: clon/ton, clonic/tonic complex; clon, clonic seizures; hyperact, hyperactivity; depr, locomotor depression; NM, NMDA; A, CPA; X, CPX.

P < 0.05, Fisher’s exact text.